已收盘 02-06 16:00:00 美东时间
+0.800
+3.67%
Enovis nimmt an der BTIG MedTech-Konferenz teil Enovis Corporation wird am Mittwoch, den 11. Februar 2026, an der BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah teilnehmen. Disclaimer: This news brief was created by Public Technologies (PUBT) u
02-03 21:01
<p>Enovis Corporation has announced that its management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026, in Snowbird, UT. The company, a global medical technology innovator, focuses on developing solutions to improve patient outcomes and restore motion. More information is available on their website, www.enovis.com, and investors are encouraged to review updates on ...
02-03 13:00
Enovis Corporation will host an investor conference call and live webcast on February 26, 2026, at 8:30 a.m. Eastern Time to discuss its 2025 fourth quarter and full year financial results. The event will also include a presentation accessible via the "Investors" section of Enovis' website. Investors can join the call by dialing (833) 685-0901 (U.S.) or (412) 317-5715 (International). A replay will be available later that day on the company's web...
01-23 13:30
The most oversold stocks in the health care sector presents an opportunity to b...
01-21 19:41
今日重点评级关注:HC Wainwright & Co.:维持MetaVia Inc."买入"评级,目标价从12美元升至40美元;Canaccord Genuity:维持GH Research"买入"评级,目标价从35美元升至39美元
01-07 17:25
BTIG analyst Ryan Zimmerman initiates coverage on Enovis (NYSE:ENOV) with a Buy rating and announces Price Target of $41.
01-06 19:31
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
2025-12-18 10:54
Freedom Capital Markets analyst Keith Hinton initiates coverage on Enovis (NYSE:ENOV) with a Buy rating and announces Price Target of $45.
2025-12-17 17:19
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 17:17
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 10:22